FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022852221> ?p ?o ?g. }

• W2022852221 endingPage "385" @default.
• W2022852221 startingPage "377" @default.
• W2022852221 abstract "Objectives– Multiple sclerosis (MS) is believed to be an autoimmune disease of the human central nervous system mediated by autoreactive T cells. Interferon-β1b (IFN-β1b) has been shown to be effective in reducing disease activity defined by clinical and magnetic resonance imaging (MRI) criteria in relapsing–remitting MS (RRMS). Yet, the exact mechanisms by which these benefits are achieved remain unknown. CD45RA is a marker for naive T lymphocytes and intercellular adhesion molecule-3 (ICAM-3) is expressed on resting lymphocytes. Material and methods– Forty-eight patients with RRMS, 24 of them treated with recombinant IFN-β1b and 24 untreated, were enrolled in this prospective study over 18 months. We investigated the percentage of CD45RA+ ICAM-3+ cells within the total lymphocyte subset in the peripheral blood serially every 3 months and in CSF once at baseline. Detailed clinical examination including Expanded Disability Status Scale (EDSS) score was performed every 3 months and cranial MRI scans were assessed every 6 months. Results– We found a temporary increase in the CD45RA+ ICAM-3+ lymphocyte ratio in peripheral blood of both untreated and IFN-β1b-treated RRMS patients. Moreover, we determined a significant negative correlation (r = −0.5874; P < 0.01) between age as well as the EDSS score (r = −0.3629; P < 0.05) and the percentages of CD45RA+ ICAM-3+ lymphocytes in peripheral blood but a positive correlation between EDSS score and the CD45RA+ ICAM-3+ ratio (r = 0.3913; P < 0.05) in the CSF at baseline. Conclusion– CD45RA+ ICAM-3+ lymphocyte ratio in peripheral blood might indicate immunosenescence in MS. However, from our data it cannot be finally concluded whether it is also influenced by IFN-β1b treatment." @default.
• W2022852221 created "2016-06-24" @default.
• W2022852221 creator A5002572392 @default.
• W2022852221 creator A5005278777 @default.
• W2022852221 creator A5016840709 @default.
• W2022852221 creator A5025080501 @default.
• W2022852221 creator A5026015195 @default.
• W2022852221 creator A5026125825 @default.
• W2022852221 creator A5028127781 @default.
• W2022852221 creator A5060330435 @default.
• W2022852221 creator A5066149769 @default.
• W2022852221 creator A5069271331 @default.
• W2022852221 creator A5074268720 @default.
• W2022852221 creator A5079394257 @default.
• W2022852221 creator A5084597037 @default.
• W2022852221 creator A5091669448 @default.
• W2022852221 date "2004-12-01" @default.
• W2022852221 modified "2023-09-24" @default.
• W2022852221 title "CD45RA+ ICAM-3+ lymphocytes in interferon-beta1b-treated and -untreated patients with relapsing-remitting multiple sclerosis" @default.
• W2022852221 cites W1968168664 @default.
• W2022852221 cites W1968642068 @default.
• W2022852221 cites W1972171487 @default.
• W2022852221 cites W1988260186 @default.
• W2022852221 cites W1996222302 @default.
• W2022852221 cites W2000599573 @default.
• W2022852221 cites W2000872418 @default.
• W2022852221 cites W2002373619 @default.
• W2022852221 cites W2008787165 @default.
• W2022852221 cites W2023155608 @default.
• W2022852221 cites W2023485889 @default.
• W2022852221 cites W2023621390 @default.
• W2022852221 cites W2023850749 @default.
• W2022852221 cites W2028107127 @default.
• W2022852221 cites W2031254657 @default.
• W2022852221 cites W2039484868 @default.
• W2022852221 cites W2040100900 @default.
• W2022852221 cites W2044173905 @default.
• W2022852221 cites W2055435762 @default.
• W2022852221 cites W2062324388 @default.
• W2022852221 cites W2078175343 @default.
• W2022852221 cites W2079800848 @default.
• W2022852221 cites W2083770877 @default.
• W2022852221 cites W2112165124 @default.
• W2022852221 cites W2118014174 @default.
• W2022852221 cites W2123226439 @default.
• W2022852221 cites W2123942662 @default.
• W2022852221 cites W2130355701 @default.
• W2022852221 cites W2135252042 @default.
• W2022852221 cites W2165547142 @default.
• W2022852221 cites W2165804863 @default.
• W2022852221 cites W2312996869 @default.
• W2022852221 cites W4234254101 @default.
• W2022852221 cites W4250145052 @default.
• W2022852221 doi "https://doi.org/10.1111/j.1600-0404.2004.00346.x" @default.
• W2022852221 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15527450" @default.
• W2022852221 hasPublicationYear "2004" @default.
• W2022852221 type Work @default.
• W2022852221 sameAs 2022852221 @default.
• W2022852221 citedByCount "8" @default.
• W2022852221 countsByYear W20228522212014 @default.
• W2022852221 countsByYear W20228522212019 @default.
• W2022852221 countsByYear W20228522212022 @default.
• W2022852221 crossrefType "journal-article" @default.
• W2022852221 hasAuthorship W2022852221A5002572392 @default.
• W2022852221 hasAuthorship W2022852221A5005278777 @default.
• W2022852221 hasAuthorship W2022852221A5016840709 @default.
• W2022852221 hasAuthorship W2022852221A5025080501 @default.
• W2022852221 hasAuthorship W2022852221A5026015195 @default.
• W2022852221 hasAuthorship W2022852221A5026125825 @default.
• W2022852221 hasAuthorship W2022852221A5028127781 @default.
• W2022852221 hasAuthorship W2022852221A5060330435 @default.
• W2022852221 hasAuthorship W2022852221A5066149769 @default.
• W2022852221 hasAuthorship W2022852221A5069271331 @default.
• W2022852221 hasAuthorship W2022852221A5074268720 @default.
• W2022852221 hasAuthorship W2022852221A5079394257 @default.
• W2022852221 hasAuthorship W2022852221A5084597037 @default.
• W2022852221 hasAuthorship W2022852221A5091669448 @default.
• W2022852221 hasBestOaLocation W20228522211 @default.
• W2022852221 hasConcept C126322002 @default.
• W2022852221 hasConcept C126838900 @default.
• W2022852221 hasConcept C143409427 @default.
• W2022852221 hasConcept C188816634 @default.
• W2022852221 hasConcept C203014093 @default.
• W2022852221 hasConcept C2777761686 @default.
• W2022852221 hasConcept C2780640218 @default.
• W2022852221 hasConcept C2780892749 @default.
• W2022852221 hasConcept C2908698914 @default.
• W2022852221 hasConcept C2994247566 @default.
• W2022852221 hasConcept C71924100 @default.
• W2022852221 hasConcept C90924648 @default.
• W2022852221 hasConceptScore W2022852221C126322002 @default.
• W2022852221 hasConceptScore W2022852221C126838900 @default.
• W2022852221 hasConceptScore W2022852221C143409427 @default.
• W2022852221 hasConceptScore W2022852221C188816634 @default.
• W2022852221 hasConceptScore W2022852221C203014093 @default.
• W2022852221 hasConceptScore W2022852221C2777761686 @default.
• W2022852221 hasConceptScore W2022852221C2780640218 @default.
• W2022852221 hasConceptScore W2022852221C2780892749 @default.

• next